OPINION Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

被引：0
作者：
DeSouza, Cyrus [2 ,3 ]
Fonseca, Vivian [1 ]
机构：
[1] Tulane Univ, Hlth Sci Ctr, 1430 Tulane Ave,SL 53, New Orleans, LA 70118 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Omaha Vet Affairs Med Ctr, Omaha, NE USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2009年 / 8卷 / 05期
关键词：
GLUCAGON-LIKE PEPTIDE-1; CYCLASE-ACTIVATING POLYPEPTIDE; NA+-GLUCOSE COTRANSPORTER; CORONARY-ARTERY-DISEASE; FACTOR-KAPPA-B; ENDOCANNABINOID SYSTEM; INTESTINAL POLYPEPTIDE; MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION; EMERGING ROLES;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The potential cardiovascular risks that are associated with drugs for type 2 diabetes have recently raised considerable clinical and regulatory concerns. As some risk factors for cardiovascular disease and type 2 diabetes are related, identifying agents that target shared underlying pathways and processes is an attractive therapeutic strategy. In this article, we review the background to and the implications of recent regulatory guidance on the development of new drugs for diabetes, and discuss the potential cardiovascular effects of selected classes of diabetes drugs that are currently being investigated.
引用
收藏
页码：361 / 367
页数：7
相关论文
共 70 条
  • [1] Nuclear factor-kappa B: From clone to clinic
    Ahn, Kwang Seok
    Sethi, Gautam
    Aggarwal, Bharat B.
    [J]. CURRENT MOLECULAR MEDICINE, 2007, 7 (07) : 619 - 637
  • [2] Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
    Arakawa, K
    Ishihara, T
    Oku, A
    Nawano, M
    Ueta, K
    Kitamura, K
    Matsumoto, M
    Saito, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (02) : 578 - 586
  • [3] Atanasov Atanas G., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P125, DOI 10.2174/187153007780832082
  • [4] Balint B. L., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P33
  • [5] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    Ban, Kiwon
    Noyan-Ashraf, M. Hossein
    Hoefer, Judith
    Bolz, Steffen-Sebastian
    Drucker, Daniel J.
    Husain, Mansoor
    [J]. CIRCULATION, 2008, 117 (18) : 2340 - 2350
  • [6] Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
    Basu, Ananda
    Charkoudian, Nisha
    Schrage, William
    Rizza, Robert A.
    Basu, Rita
    Joyner, Michael J.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (05): : E1289 - E1295
  • [7] Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic β-cells and effects of PACAP-38 on components of the insulin secretory system
    Borboni, P
    Porzio, O
    Pierucci, D
    Cicconi, S
    Magnaterra, R
    Federici, M
    Sesti, G
    Lauro, D
    D'Agata, V
    Cavallaro, S
    Marlier, LNJL
    [J]. ENDOCRINOLOGY, 1999, 140 (12) : 5530 - 5537
  • [8] Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity
    Cabou, Cendrine
    Campistron, Gerard
    Marsollier, Nicolas
    Leloup, Corinne
    Cruciani-Guglielmacci, Celine
    Penicaud, Luc
    Drucker, Daniel J.
    Magnan, Christophe
    Burcelin, Remy
    [J]. DIABETES, 2008, 57 (10) : 2577 - 2587
  • [9] Charles M Arthur, 2005, Diabetes Technol Ther, V7, P818, DOI 10.1089/dia.2005.7.818
  • [10] DAVIES MJ, 2005, DIABETIC MED, V22, pS6
1234567